Recital 14, Directive (EU) 2004/27

In forcesince 31 Mar 2004cited 2×

Since generic medicines account for a major part of the market in medicinal products, their access to the Community market should be facilitated in the light of the experience acquired. Furthermore, the period for protection of data relating to pre-clinical tests and clinical trials should be harmonised.

  • Judgment of the Court (Fifth Chamber), 23 October 2014. Olainfarm AS v Latvijas Republikas Veselības ministrija and Zāļu valsts aģentūra.Decision

    Recital 14 in the preamble to Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83 (OJ 2004 L 136, p. 34) is worded as follows: ‘Since generic medicines account for a major part …

    23 Oct 2014 · 62013CJ0104

  • Opinion of Advocate General Kokott delivered on 4 October 2018. Staat der Nederlanden v Warner-Lambert Company LLC.Decision

    This consequence is nevertheless consistent with the spirit and purpose of the carve-out arrangement in the second sentence of Article 11 of Directive 2001/83, as that provision was introduced not only to promote quick market entry for …

    4 Oct 2018 · 62017CC0423